HK1002457A1 - Angiostatin fragments and methods of use - Google Patents

Angiostatin fragments and methods of use

Info

Publication number
HK1002457A1
HK1002457A1 HK98101446A HK98101446A HK1002457A1 HK 1002457 A1 HK1002457 A1 HK 1002457A1 HK 98101446 A HK98101446 A HK 98101446A HK 98101446 A HK98101446 A HK 98101446A HK 1002457 A1 HK1002457 A1 HK 1002457A1
Authority
HK
Hong Kong
Prior art keywords
angiostatin
fragments
methods
proliferation inhibitor
aggregate
Prior art date
Application number
HK98101446A
Other languages
English (en)
Inventor
M Judah Folkman
Michael S O'reilly
Yihai Cao
Jie Lin
Original Assignee
Chiodren S Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/429,743 external-priority patent/US5885795A/en
Priority claimed from US08/605,598 external-priority patent/US5861372A/en
Priority claimed from US08/612,788 external-priority patent/US5837682A/en
Application filed by Chiodren S Medical Ct Corp filed Critical Chiodren S Medical Ct Corp
Publication of HK1002457A1 publication Critical patent/HK1002457A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK98101446A 1995-04-26 1998-02-25 Angiostatin fragments and methods of use HK1002457A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/429,743 US5885795A (en) 1994-04-26 1995-04-26 Methods of expressing angiostatic protein
US08/605,598 US5861372A (en) 1996-02-22 1996-02-22 Aggregate angiostatin and method of use
US08/612,788 US5837682A (en) 1996-03-08 1996-03-08 Angiostatin fragments and method of use
PCT/US1996/005856 WO1996035774A2 (en) 1995-04-26 1996-04-26 Angiostatin fragments and aggregate angiostatin and methods of use

Publications (1)

Publication Number Publication Date
HK1002457A1 true HK1002457A1 (en) 1998-08-28

Family

ID=27411639

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98101446A HK1002457A1 (en) 1995-04-26 1998-02-25 Angiostatin fragments and methods of use

Country Status (17)

Country Link
EP (1) EP0824546B1 (zh)
JP (2) JP3787157B2 (zh)
CN (1) CN1195375A (zh)
AT (1) ATE368051T1 (zh)
AU (1) AU709633B2 (zh)
BR (1) BR9608326A (zh)
CA (1) CA2219081C (zh)
CZ (1) CZ334097A3 (zh)
DE (1) DE69637179T2 (zh)
ES (1) ES2292174T3 (zh)
HK (1) HK1002457A1 (zh)
HU (1) HUP9800784A3 (zh)
MX (1) MX9708217A (zh)
NO (1) NO974943L (zh)
NZ (1) NZ307044A (zh)
PL (1) PL323256A1 (zh)
WO (1) WO1996035774A2 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
DE69631972T2 (de) * 1995-12-13 2005-01-05 The Children's Medical Center Corp., Boston Proliferationsinhibitor von endothellzellen und dessen verwendung
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
EP1705248A1 (en) * 1997-10-01 2006-09-27 G.D. Searle LLC. Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO1999029855A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
CA2263784A1 (en) 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses
ATE408415T1 (de) * 1998-04-28 2008-10-15 Toshikazu Nakamura Inhibitoren für die gefässneubildung
WO1999061464A1 (en) * 1998-05-28 1999-12-02 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
US6420335B1 (en) 1998-06-15 2002-07-16 Dana Farber Cancer Institute, Inc. Combination of radiotherapy and anti-angiogenic factors
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1147202A2 (en) * 1999-01-28 2001-10-24 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
JP4666767B2 (ja) * 1999-02-10 2011-04-06 ザ チルドレンズ メディカル センター コーポレイション プラスミノーゲンの脱グリコシル化クリングル１〜５領域フラグメント及びこれらの使用方法
US7157556B1 (en) 1999-02-10 2007-01-02 The Children's Medical Center Corporation Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
AR030631A1 (es) * 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
EP1713511B1 (en) * 2004-01-09 2011-11-09 Mogam Biotechnology Research Institute Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
CA2557154A1 (en) * 2004-02-24 2005-09-01 Ttc Co., Ltd. Anticancer agent containing bl-angiostatin
ITMI20041962A1 (it) * 2004-10-15 2005-01-15 Istituto Naz Per La Ricerca S "peptide di angiostatina e suoi impieghio terapeutici"
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2010070746A1 (ja) * 2008-12-17 2010-06-24 株式会社ティムス イヌアンジオスタチン様ポリペプチド
JP5749229B2 (ja) * 2012-07-31 2015-07-15 京セラドキュメントソリューションズ株式会社 ジェスチャー管理プログラム及び情報処理装置
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
WO2017101868A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CA3047173A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Use of plasminogen for promoting insulin secretion for treatment of diabetes
EP3675889A4 (en) 2017-08-31 2021-05-12 Singapore Health Services PTE Ltd ANGIO -3 FOR THE TREATMENT OF ANGIOGENIC RETINAL DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76095A (en) * 1994-04-26 1997-06-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis

Also Published As

Publication number Publication date
AU709633B2 (en) 1999-09-02
EP0824546B1 (en) 2007-07-25
NO974943D0 (no) 1997-10-24
DE69637179D1 (de) 2007-09-06
HUP9800784A2 (hu) 1998-07-28
ES2292174T3 (es) 2008-03-01
JPH11508228A (ja) 1999-07-21
NO974943L (no) 1997-12-18
DE69637179T2 (de) 2008-04-10
CN1195375A (zh) 1998-10-07
BR9608326A (pt) 2000-03-08
JP3787157B2 (ja) 2006-06-21
NZ307044A (en) 2002-03-01
CA2219081A1 (en) 1996-11-14
CA2219081C (en) 2004-02-24
JP2001151691A (ja) 2001-06-05
EP0824546A2 (en) 1998-02-25
AU5579596A (en) 1996-11-29
PL323256A1 (en) 1998-03-16
ATE368051T1 (de) 2007-08-15
HUP9800784A3 (en) 2000-07-28
MX9708217A (es) 1997-12-31
CZ334097A3 (cs) 1998-04-15
WO1996035774A3 (en) 1997-02-13
WO1996035774A2 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
HK1002457A1 (en) Angiostatin fragments and methods of use
CA2291892A1 (en) Angiostatin fragments and method of use
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
ATE214075T1 (de) Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
CA2391098A1 (en) Recombinant .alpha.-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
PL331240A1 (en) Cut off soluble tumour necrosis factor receptors of i and ii type
DE69737397D1 (de) Verwendung von mif-antagonisten zur krebstherapie
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
CA2259960A1 (en) Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
EP1009755A4 (en) STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME
PL327181A1 (en) Benzofurane carboxyamides and sulphonamides
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
NZ334592A (en) Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer
WO2003026580A3 (en) Interactive therapeutic enclosures
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
WO1999057133A3 (en) Inhibitors of nf-kb activation
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
AU6291799A (en) Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
AU4823999A (en) Methods and compositions for treating diseases mediated by transglutaminase activity
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20160425